Caribou Biosciences, Inc.
CRBUNASDAQHealthcare● Active
$1.65
+$0.06(+3.45%)
Market Cap$163647949
P/E Ratio—
52W High$3.535
52W Low$1.04
Caribou Biosciences, Inc. (CRBU) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CRBU · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($148.13M) | ($149.10M) | ($102.07M) | ($99.42M) | ($66.92M) |
| Depreciation & Amort. | $3.65M | $3.93M | $3.52M | $3.64M | $0.98M |
| Stock-Based Comp. | $12.68M | $16.71M | $13.75M | $11.72M | $3.45M |
| Change in Working Capital | ($0.48M) | ($5.11M) | ($7.32M) | ($4.11M) | $29.07M |
| Net Cash from Operations | ($110.99M) | ($138.20M) | ($93.29M) | ($90.97M) | ($32.52M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.36M) | ($6.50M) | ($11.61M) | ($6.45M) | ($3.12M) |
| Purchases of Investments | ($150.37M) | ($304.39M) | ($394.76M) | ($339.06M) | ($173.28M) |
| Sales of Investments | $252.83M | $397.49M | $338.19M | $252.87M | $0.00M |
| Net Cash from Investing | $102.24M | $86.61M | ($68.18M) | ($93.25M) | ($176.40M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $1.03M |
| Net Cash from Financing | $4.82M | $16.72M | $154.30M | $2.13M | $433.43M |
| Free Cash Flow | |||||
| Free Cash Flow | ($112.35M) | ($144.71M) | ($104.90M) | ($97.42M) | ($35.64M) |
| FCF Margin %(computed) | — | — | -304.27% | -703.34% | -371.33% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Caribou Biosciences, Inc. data
About Caribou Biosciences, Inc. (CRBU) Cash Flow Statement
Caribou Biosciences, Inc. generated operating cash flow of ($0.11B) and free cash flow of ($0.11B) for 2025 — a FCF margin of -1006.82%. Capital expenditure was ($0.00B).
Frequently asked questions
CRBU · 4 questionsCaribou Biosciences, Inc. generated free cash flow of ($0.11B) for 2025, up 22.4% year-over-year.
CRBU free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15